The case for fixing Canada’s innovation gap
The global rules governing how innovative medicines are valued and priced are being rewritten— and Canada must be ready. By […]
Drugs for rare diseases (DRD)
Increasing timely access to medicines for patients suffering from rare diseases.
One in 12 Canadians, two-thirds of them children, lives with a rare disease. IMC advocates for policies that improve and accelerate access to the medicines and treatments these patients urgently need.
Canada needs to deliver on its rare disease strategy to enable better patient care and timely access to treatments.
News
The role of pharma on the path to new medicines: A conversation with IMC by Lung Cancer Canada
Dr. Paul Wheatley-Price chats with IMC President & CEO, Dr. Bettina Hamelin in this episode, covering off what IMC does, the role of […]
Canada’s rare disease strategy: A critical test for innovation, access, and equity
As originally published in BIOTEC Insights magazine here, June 17, 2025. Authored by: Dr. Bettina Hamelin President, Innovative Medicines Canada For the […]
Government Submissions
Addendum to IMC submission on drugs for rare diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
Towards a value-based and pan-Canadian rare disease strategy
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
Analysis and Reports
The value of the innovative pharmaceutical industry – A report summary
This summary of a study by Deloitte combines a traditional economic impact analysis with targeted assessments of health system impacts […]
The Canadian research and development pharmaceutical sector, 2022
This study examines the contribution of Canada’s research and development (R&D) pharmaceutical sector to the Canadian economy in 2022. It builds upon the annual reports produced since 2018.
Newsroom
Breaking down key developments in the life sciences sector for members, policy influencers, and Canadians.
About
Learn how our member companies, which range from early-stage startups to established organizations, are advancing healthcare through the discovery and development of new medicines and vaccines.
